::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

TREATMENT OF HELICOBACTER PYLORI INFECTION: CURRENT AND FUTURE INSIGHTS

AUTHORS:

Dr. Fatima Kausar, Dr. Muhammad Haseeb, Dr. Komal Junaid

ABSTRACT:

One of the major worldwide cause of gastric malignancies such as mucosa associated lymphoid tissue lymphoma, peptic ulcer and gastric adenocarcinoma is Helicobacter pylori (H. pylori). The treatment of H. pylori is still a daunting task for the clinicians because for successful therapy, successful eradication of this microbe is imperative. Primary or secondary determinants like mucosal drug concentration, patient compliance, antibiotic resistance, cost and side- effect profile. However, no new drug has been introduced yet, so the current therapy relies upon a mixture of antibiotics used for its treatment and anti – secretory agents. Various treatment regimens like double therapy, quadruplet therapy are also in practice, but Levofloxacin containing triple treatment is best known for finely fighting against H. pylori after first line battle. One issue that is very prominent is the development of drug resistance in the microbe. Therefore, the future of probiotic medication, phytomedicine and H. pylori vaccine look more promising against H. pylori and its diseases. This review paper encompasses these current and future perspectives of the treatment of H. pylori.